Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02435628
Other study ID # 2014P002755
Secondary ID
Status Completed
Phase N/A
First received April 29, 2015
Last updated April 2, 2017
Start date February 2015
Est. completion date September 2016

Study information

Verified date April 2017
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective study through the NF clinic at Massachusetts General Hospital that will examine the relationship between psychosocial factors, health literacy, and satisfaction with the medical visit in adults with NF1, NF2, and Schwannomatosis. A total of 89 participants will be enrolled in the study.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date September 2016
Est. primary completion date September 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age 18 or older

2. Can read and speak English at or above the 6th grade level

3. Diagnosis of neurofibromatosis type 1, neurofibromatosis type 2, or schwannomatosis

Exclusion Criteria:

1. Severe active or untreated major mental illness that would interfere with study participation, to be determined at the discretion of the study investigator (e.g. untreated psychosis or suicidality)

2. Unable or unwilling to participate

3. Unable or unwilling to complete psychological assessments online via the REDCap or Assessment Center systems.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaires
All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Age, Gender, Ethnicity, and Race of Patients with NF The questionnaire asks for the patient's age, gender, ethnicity, and race as part of the basic demographics. Baseline (pre-medical visit)
Other Visual Analog Health Scale Measures one's current health on a scale from 0 ("very poor") to 10 ("very good"). Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
Other Learning Disabilities of Patients with NF This question asks patients if they have ever been diagnosed with a learning disability. Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
Other First Time at NF Clinic This question asks the patient if it's their first time at the MGH NF clinic. Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
Primary Patient Reported Outcomes Measurement Information System (PROMIS) A battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Baseline (pre-medical visit)
Primary Functional, Communicative and Critical Health Literacy (FFFHL) scale Measures one's health literacy, the capacity of individuals to access, understand, and use health information to make informed and appropriate health-related decisions. Baseline (pre-medical visit)
Primary Medical Interview Satisfaction Scale (MISS) Measures patient satisfaction with individual doctor-patient consultations. Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
Primary Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey Asks patients to report on and evaluate their experiences with health care. This survey covers topics that are important to consumers and focus on aspects of quality that consumers are best qualified to assess, such as the communication skills of providers and ease of access to health care services. Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
See also
  Status Clinical Trial Phase
Completed NCT00754780 - Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Phase 2
Completed NCT00589784 - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Phase 2
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Completed NCT01673009 - Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Phase 2
Recruiting NCT00598351 - Natural History Study of Patients With Neurofibromatosis Type 2
Completed NCT02298270 - Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype N/A
Terminated NCT01402817 - Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Phase 2
Completed NCT02101736 - Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Phase 2
Completed NCT01633008 - Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain Early Phase 1
Terminated NCT04461886 - A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I Phase 3
Completed NCT01275586 - Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Early Phase 1
Active, not recruiting NCT01140360 - Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Phase 1/Phase 2
Completed NCT02211768 - Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Phase 1
Completed NCT00508235 - Quality of Friendships in Children With Neurofibromatosis N/A
Completed NCT01639950 - Validating Pain Scales in Children and Young Adults